Actinidia Chinensis Planch roots (acRoots) are used to treat many cancers, although the antitumor mechanism by which acRoots inhibit cancer cell growth remains unclear. The present study aims at investigating inhibitory effects of acRoots on human lung cancer cells and potential mechanisms. Our data demonstrate that the inhibitory effects of acRoots on lung cancer cells depend on genetic backgrounds and phenotypes of cells. We furthermore found the expression of metabolism-associated gene profiles varied between acRoots-hypersensitive (H460) or hyposensitive lung cancer cells (H1299) after screening lung cancer cells with different genetic backgrounds. We selected retinoic acid receptor beta (RARB) as the core target within metabolism-associated core gene networks and evaluated RARB changes and roles in cells treated with acRoots at different concentrations and timeframes. Hypersensitive cancer cells with the deletion of RARB expression did not response to the treatment with acRoots, while RARB deletion did not change effects of acRoots on hyposensitive cells. Thus, it seems that RARB as the core target within metabolism-associated networks plays important roles in the regulation of lung cancer cell sensitivity to acRoots.
Background
Actinidia Chinensis Planch roots (acRoots) as one of Chinese traditional medicine has therapeutic roles in detoxification, blood swelling, or stroke. Of 60 types, Actinidia Chinensis Planch is a liana plant and grows in temperate climate zones. Seven chemical components were identified from the root of acRoots, including 2alpha-hydroxyoleanolic acid, 2alpha-hydroxyursolic acid, euscaphic acid, 23-hydroxyursolic acid, 3beta-Oacetylursolic acid, ergosta4, 6, 8, 14, 22-tetraen-3-one, and beta-steriol [1] . acRoots is used to treat cancers in stomach, lung, nasopharynges, liver, or colon [2] [3] [4] , although the mechanism by which acRoots inhibit cancer cell growth remains unclear.
Liver cancer cell sensitivity was found to be associated with cellular immunity and inflammation gene clusters, of which prostaglandin E receptor 3 was as a key regulator of gene expression in response to acRoots [4] . The present study evaluates the inhibitory effects of acRoots on lung cancer cells with different genetic backgrounds and measured dynamic alterations of metabolism-associated gene clusters after the treatment with acRoots at various concentrations. We define metabolism-associated gene networks and the core target within the network of lung cancer cells hypersensitive or hyposensitive to acRoots and investigate the potential mechanism of acRoots inhibition.
Methods
Cell source and culture Lung cancer cells with different genetic backgrounds, e.g. NCI-H358, NCI-H460, NCI-H661, NCI-H1299, NCI-H1650, A549, SPC-A1, or HBE135-E6E7, were provided by cell bank of Shanghai Institutes for Biological Sciences (Shanghai, China). NCI-H358 is non-small cell lung cancer with complete homozygous deletion of the p53 gene and with 2240 mutations and 60 genes with altered copy number. NCI-H460 is large cell lung carcinoma with about 700 mutations and 450 genes with altered copy number. NCI-H661 is large cell lung cancer with 1600 mutations and 2500 genes with altered copy number. NCI-H1299 is non-small cell lung cancer with 980 mutations and 2000 genes with altered copy number. NCI-H1650 is lung adenocarcinoma with 320 mutations and 430 genes with altered copy number. A549 is a lung adenocarcinoma with the KRAS mutation (p.G12Sc.34G>A), 710 mutations, and
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Wang et al. Molecular and Cellular Therapies (2017) 5:2 210 genes with altered copy number. SPC-A1 is a lung adenocarcinoma without gene copy number variation. HBE135-E6E7, derived from normal bronchial epithelium taken from a man with squamous cell carcinoma, express high levels of mRNA for epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha), and amphiregulin (AR), but not epidermal growth factor (EGF). All cells were cultured in RPMI 1640 medium (Biowest, France) supplemented with 10% inactivated fetal bovine serum (Biowest), under certain circumstances of humidified air at 37°C with 5% CO 2 .
acRoots preparation acRoots were mashed and mixed with tenfold double distilled water, with 100°C heat for an hour. After 2 cycles of procedures of filtration, the extract was concentrated into 1g/ml ultimately. 
Cell screening

Validation of the Microarray Genes
After the bioinformatics analysis, the selected genes were validated by NCI-H358, NCI-H460, NCI-H661, NCI-H1299, NCI-H1650, A549, SPC-A1 and HBE135-E6E7 cells. The cells (5×10 4 /well) were seed in 24-well plates for 24 hours incubation and then treated with acRoots at 10mg/ml for 48 hours. After the termination, total RNA was prepared with TRIzol reagent (Invitrogen, USA). Complementary DNA was synthesized using reverse transcription reagent kit (TaKaRa, Japan) from 1μg of total RNA. Real-time PCR was performed using the following primers by PrimeScript ® RT reagent Kit (TaKaRa). Amplification and detection of mRNA were analyzed by 7500 real-time PCR System (Applied Biosystems, USA). The relative amount of gene was normalized against the glyceraldehyde-3-phosphate dehydrogenase mRNA. All real-time PCRs were performed in triplicate, and the changes in gene expression were exhibited as fold-increases relative to untreated controls.
Cell transfection and RNA interference
A f t e r t h e s e l e c t i o n a n d v a l i d a t i o n i n N C I -H 3 5 8 , N C I -H 4 6 0 , N C I -H 6 6 1 , N C I -H 1 2 9 9 , N C I -H 1 6 5 0 , A549, SPC-A1 and HBE135-E6E7 cells, RARB gene was chosen as the core target within metabolisma s s o c i a t e d n e t w o r k s a n d t r a n s f e c t e d w i t h s m a l l interference RARB RNA in H460 cell. After 24 hour incubation, cells were treated with RARB-SiRNA (RARB-Homo-999: GACGAUCUCACAGAGAAGATT,
UUCUCCGAACGUGUCACGUTT, ACGUGACACGUUCGGAGAATT) (GenePharma, China) at 0.01, 0.1, or 1.0 umol/L. Lipofectamine 2000 transfection reagent (Invitrogen, USA) at 2ul/ml per well was used for 6 hours and changed to the complete cell culture medium for 24, 48 or 72 hours. Total RNA was prepared with TRIzol reagent and complementary DNA was synthesized using reverse transcription reagent kit (TaKaRa, Japan) from 1μg of total RNA to measure gene expression of RARB. After screening out the optimal cell transfection and RNA interference condition, cells were treated with acRoots at 0, 5, 10, or 30 mg/ml for 24 hours to detect cell proliferation and gene expression of RARB.
Results
Inhibitory effects of acRoots on lung cancer cells
The cell sensitivity to the drug was screened and evaluated using concentrations of acRoots from 1 to 100 mg/ml and dynamically from 24 to 72 hours. Of those cells, H1299 cell proliferations were significantly inhibited from 5 mg/ml of acRoots with a concentrationdependent pattern ( Figure 1A ). SPC-A1 cell significantly increased from 3 mg/ml ( Figure 1B ). HBE cells became hypersensitive to acRoots from 3 mg/ml and died from 5 mg/ml ( Figure 1C ). Significant inhibition of acRoots was noticed in A549 ( Figure 1D ), H661 ( Figure 1E ), or H358 cells ( Figure 1F ) at 30 mg/ml. The proliferations of H460 ( Figure 1G ) and H1650 ( Figure 1H ) cells were significantly inhibited by acRoots from 50 mg/ml. To further evaluate the concentration window, H460 cells were treated with acRoots at 10, 20, 30, 40, or 50 mg/ml for 24 hours and showed hypersensitive to the drug from 20 mg/ml in a concentration-dependent pattern ( Figure 1I ). Thus, H1299 cells were selected as an acRoots-hypersensitive representative, while H460 as hyposensitive one.
Expression of metabolism-associated gene clusters
The expression of about 39888 genes was changed in H1299 and H460 cells after the treatment with acRoots (Supplement 1). The expression of metabolism-associated gene clusters in H460 cell was shown in Figure 2A , of which some were continuously up-regulated ( Figure 2B ) or down-regulated ( Figure 2C ). We summarized eight dynamic change pattern in Figure 2D where the number of genes in each pattern were listed. Figure 2E showed top 10 of genes in the mode of consistent down-regulation as an example. Of those selected genes, interleukin 21 receptor (IL21R), putrescine/proton symporter ankyrin domain family member D (POTED), and nuclear protein 1 (NUPR1) were selected and furthermore validated in different lung cancer cells. Our results indicate some of selected genes were altered in the same pattern as microarray showed ( Figure 2F ), even though the same gene probes were used. Figure 3A showed the alterations of genes in H1299 cells after treatment with acRoots at 1, 5, or 10 mg/ml. The eight change patterns of metabolism-associated genes with gene numbers were presented in Figure 3E . Of those, 7 genes consistently increased ( Figure 3B ), 8 or 24 genes similarly decreased between 1 and 5 mg/ml ( Figure  3C ) or between 5 and 10 mg/ml ( Figure 3E ), or 60 genes decreased maximally from 1 mg/ml ( Figure 3F ). Three selected genes, e.g. heat shock protein family A member 6 (HSPA6), discoidin domain receptor (DDR), and G proteincoupled receptor 12 (GPR12) were further validated in different cells. We noted the expression of selected genes in most of cells reduced, while HSPA6 increased in HBE, H1650, or H1299 ( Figure 3G ).
Selection of the core target within networks
Different concentrations and treatment schedule were selected between H460 and H1299 cells, after the screening of acRoots inhibitory effects ( Figure 4A ). The distribution of changed genes in H460 ( Figure 4B Figure 5A ). We found that concentration-associated expressions of selected genes were not consistent with RARB gene changes ( Figure 5A ). Of those selected genes within network, HDAC1, SRC, NCOA1, NCOA2, NCOA3, and EP300 were found in one signaling pathway-thyroid hormone signaling pathway ( Figure 5B ).
Validation of RARB-dominant mechanisms
RARB-dominant signaling pathway demonstrates that most of associated factors in the RARB-driven mechanism have the similar change patterns, even though the patterns were different from RARB one ( Figure 6 ). H460 cells have the highest expression of RARB gene without acRoots, as compared with other lung cancer cells, and A549 and H1299 cells were the second high expression of RARB which is about one third of H460 ( Figure 7A) . In order to define the sensitivity of H460 RARB expression to challenges, inflammatory stimulus lipopolysaccharide (LPS) from Salmonella typhi used in the present study could slightly up-regulate RARB expression at the early stage (4 and 8 hours) after the challenge (Figure 7B ), while significantly down-regulate RARB from 24 and on in a dose-dependent pattern ( Figure 7C ). LPS at dose of 1.0 μmol down-regulated RARB expression almost 100% at 24 hours, while about 60% at 72 hours. Designed GAPDH gene small interfering RNA (siRNA) in H460 cells has the interference efficiency over 95% ( Figure 7D ) to validate the process of siRNA synthesis.
We furthermore designed four RARB siRNA targeting sequences and found that the interference efficiency of RARB siRNA-1140 in H460 was higher than 80% ( Figure  8A ). The combination of acRoots and RARB siRNA could turn off the expression of RARB genes 24 hours after the treatment. The proliferation of H460 cells significantly increased after the deletion of RARB gene, as compared with cells without deletion or with sham small interference ( Figure 8B ). The most important finding was that the proliferation of H460 with RARB siRNA significantly decreased from 24 hours and on after acRoots at 5 mg/ The cytochrome P450 monooxygenases (CYP) and its isoforms are the primary retinoid-inactivating enzyme and regulates the embolism. We found that the expression of CYP26A1 ( Figure 8C ) and CYP2E1 ( Figure 8D ) did not change, while CYP26B1 ( Figure 8E ) increased after treatment with acRoots at 5, 10, or 30 mg/ml. The deletion of RARB gene could completely down-regulate the expression of CYP26A1 and CYP26B1, while up-regulate CYP2E1 about 5 folds over cells with RARB. Those RARB siRNA-induced changes were reserved with acRoots from 5 mg/ml.
Discussion
Our results show inhibitory effects of acRoots in lung cancer cells with different genetic backgrounds, which are associated with the variation of sensitivities to the drug. The anti-tumor effect of acRoots was suggested to be associated the activation of the p38 mitogenactivated protein kinase, Caspase9, or poly-(ADP-ribose) polymerase signal pathways, the induction of apoptosis, or cell death [6] . The inhibitory effects of acRoots in lung cancer cells was due to the cytotoxic activity of phenolic elements from acRoots [2] . There is little to know how lung cancer cells develop various sensitivities to acRoots and what the critical limiting factors are in the regulation of cell susceptibility. Study on kiwifruit gene sequencing, structure, and transcript abundance at developmental stages demonstrated that critical genes are mainly involved in the biosynthesis and metabolism of elements, especially in sucrose and starch metabolism [7] . It indicates that metabolism-associated genes play important roles in the development of kiwifruit and trucks.
We hypothesize that acRoots interact with metabolisma s s o c i a t e d g e n e s a n d p a t h w a y s i n c a n c e r c e l l s reciprocally to inhibit cancer cell growth and metastasis. The previous studies from our group demonstrated that acRoots could influence the expression of cholesterol metabolism-associated genes in hepatocellular carcinoma [8] . acRoots could influence cholesterol synthesis and uptake of cancer cells, probably through the activation of proprotein convertase subtilisin/kexin type 9, resulting in the reduction of lipid receptor expression and uptake, total intracellular cholesterol, and cell proliferation. effects in a concentration-dependent pattern, in order to avoid the cytotoxicity of drugs and have a biological window for intervention [9] . We found both H1229 and HBE cells hypersensitive to acRoots and selected H1299 as the hypersensitive representative, since H1299 cells showed a clear concentration-dependent inhibition, high malignance, and more gene mutations, as compared with HBE cells. Among H460, H1650, A549, H661, and H358 cells in response of high concentrations of acRoots, we found that A549 and H1650 cells failed to show the acRoots-concentration-dependent inhibition, though we tried to different concentrations of acRoots between 10 and 30 mg/ml. H661 and H358 cells have the low capacity of proliferation and a small window between with or without effects. As the hyposensitive representative, H460 cells a clear acRoots concentration-dependent inhibition between 10 and 50 mg/ml at 24 hours after the treatment. More investigations are to be needed to furthermore clarify the specificity of H1299 cell hypersensitivity or H460 cell hyposensitivity to acRoots.
The heterogeneity of cell sensitivity to drug is highly dependent genetic factors. The gene expression, mutation, and epigenetics are associated with a large range of efficacy, adverse reactions, or toxicity and account for the hypersensitivity and hyposensitivity seen in different patients [10] . The present study at the first time investigates the influence of acRoots in gene expression profiles of lung cancer cells to identify the genomic difference between acRoots-hypersensitive and hyposensitive lung cancer cells. We defined the hypersensitivity-specific (e.g. HSPA6, DDR2, GPR12) or hyposensitivity-specific metabolism-associated gene profiles (e.g. IL21R, POTED and NUPR1) as well as coexpression of some genes in both. One strategy to improve the cell sensitivity is to down-regulate or up-regulate hypersensitivity-specific or hyposensitivity-specific genes. However, the present study found that RARB as the most common metabolism pathway was obviously downregulated in both hypersensitive and hyposensitive lung cancer cells, while cells did have different sensitivities. We propose whether the down-regulation of RARB gene can augment the sensitivity of hyposensitive cells.
RARB is a member of the retinoic acid receptor subfamily, together with others, dominantly regulates the retinoic acid activity through binding specific retinoic acid response elements in target genes promoters. RARB is one of critical ligand-regulated transcription factors to centralize the cancer cell growth and metastasis through the RA and retinoid signaling pathways [11] . RARB was suggested as a potential therapeutic target to protect from solid tumors by the frequent epigenetic silencing of RARB [12] . Comprehensive expression of retinoic acid receptors in non-small cell lung cancer tissue was about up to 60% lower than in the normal [13] , while extensive retinoidbased therapies, e.g. synthetic agonists and antagonists of retinoic acid receptors, failed to the expected outcomes The integration of the gene expression with gene interactions and networks provides a better view to understand the role of selected core targets in multiple signal pathways. We developed an individualized network model to integrate differential gene expression, variance, and gene-pairs with the differential expression covariance and to define the heterogeneity of disease samples [15] . It is important to define differential gene networks of individuals, differential expression variance/covariance, and expression state or activity of various feature genes and their network or modules for an individual. We explored the transcriptional regulatory networks between subtypes of lung cancer and selected the core elements within networks to drive the force of interactions among modules [16] . In a large number of networks, we identified a network constructed with elements with significant changes after treatment with acRoots and found that RARB is the driver force among interactions and networks in hypersensitive or hyposensitive lung cancer cells. The target genes identified from gene interactions and networks were validated and confirmed as core genes in lung cancer [17] . From the molecular mechanism of retinal acid-RARB-signal pathways, we found the variation of acRoots-altered gene expressions of involved factors, even though those might interact or signal each other. In addition to gene expression, gene epigenetics should be considered, since methylation changes are specific for risk factors in lung cancer and DNA methylation changes are associated with the development of lung cancer [18] .
The fact that RARB expression in both hypersensitive and hyposensitive lung cancer cells reduced in acRoots concentration-dependent pattern demonstrates that RARB is strongly associated with inhibitory effects of acRoots. It seems that acRoots inhibit lung cancer cell proliferation through the alterations of lipids and lipidsoluble ligands regulated by nuclear hormone receptors. Our data demonstrate that acRoots inhibited RARB expression and heterodimer formation, resulting in the disconnection with and accumulations of the retinoid X receptor. The dysfunctional interaction between retinoic acid receptors and retinoid X receptors compromises the recognition and responsiveness to retinoic acid, oxysterols, polyunsaturated and oxidized fatty acids, and 1α,25-dihydroxyvitamin.D3 [19] . However, the complete deletion of RARB gene increased the proliferation of hyposensitive lung cancer cells and the cell sensitivity to acRoots. It is possible that other compensative pathways occur when RARB is deleted or blocked, although the exact compensation and mechanism need to be furthermore explored. Another question is whether acRoots-induced down-regulation of RARB is acRoots inhibition-specific or a general reaction of the compensation, since we found that LPS could also induce the down-regulation of RARB gene. It is also critical to validate the repeatability and stability of RARB-interacted elements in metabolism-associated network as efficacy-specific biomarkers and druggable targets [21] [22] [23] [24] [25] [26] .
RARB has a close communication and interaction with CYP26A1, CYP26B1 and CYP2E1 in the RARB-dominant signaling pathway. Of those, CYP26A1 plays a key role in retinoic acid metabolism and acts with all-trans-retinoic acid, to make 4-hydroxylation and 18-hydroxylation and generate hydroxylated forms of 4-OH-, 18-OH, or 4-oxoretinoid acid [20] . acRoots elevated the expression of CYP26A1 gene in hypersensitive cells and CYP26B1 in hyposensitive cells, while CYP2E1 in both. The deletion of RARB completely down-regulated the expression of CYP26A1, CYP26B1, and CYP2E1, while acRoots could restore partial expression (about 50-60%) of CYP26A1 or CYP26B1, rather than CYP2E1.
Conclusions
In conclusion, we firstly screened concentration-or time-dependent inhibitory effects of acRoots in lung cancer cells with different genetic backgrounds to select a hypersensitive (H1299 cells) or hyposensitive r e p r e s e n t a t i v e s ( H 4 6 0 c e l l s ) . We i d e n t i f i e d t h e hypersensitivity-or hyposensitivity-specific metabolismassociated gene clusters and co-expression of genes in both. We explores the interactions and networks of metabolism-associated genes in hypersensitive and hyposensitive cells treated with or without acRoots and defined the RARB-driven network as the core elements. RARB expression in both hypersensitive and hyposensitive lung cancer cells reduced in acRoots concentrationdependent pattern demonstrates. The deletion of RARB gene increased the proliferation of hyposensitive lung cancer cells and the cell sensitivity to acRoots. Thus, our data indicate that the RARB-dominant network and signal plays the important role in the regulation of lung cancer cell sensitivity to drug, although the specificity of RARBdominant sensitivity needs to be further validated.
